These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25216370)

  • 1. Preclinical models: needed in translation? A Pro/Con debate.
    Philips T; Rothstein JD; Pouladi MA
    Mov Disord; 2014 Sep; 29(11):1391-6. PubMed ID: 25216370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translating Antisense Technology into a Treatment for Huntington's Disease.
    Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
    Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.
    Miniarikova J; Evers MM; Konstantinova P
    Mol Ther; 2018 Apr; 26(4):947-962. PubMed ID: 29503201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mind the gap: models in multiple species needed for therapeutic development in Huntington's disease.
    Howland DS; Munoz-Sanjuan I
    Mov Disord; 2014 Sep; 29(11):1397-403. PubMed ID: 25155258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Animal models of Huntington's disease for translation to the clinic: best practices.
    Menalled L; Brunner D
    Mov Disord; 2014 Sep; 29(11):1375-90. PubMed ID: 25216369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonhuman Primate Models of Huntington's Disease and Their Application in Translational Research.
    Aron Badin R
    Methods Mol Biol; 2018; 1780():267-284. PubMed ID: 29856024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Environmental factors as modulators of neurodegeneration: insights from gene-environment interactions in Huntington's disease.
    Mo C; Hannan AJ; Renoir T
    Neurosci Biobehav Rev; 2015 May; 52():178-92. PubMed ID: 25770041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxicity models of Huntington's disease and relevance of hormetic mechanisms: A critical assessment of experimental approaches and strategies.
    Calabrese EJ; Bhatia TN; Calabrese V; Dhawan G; Giordano J; Hanekamp YN; Kapoor R; Kozumbo WJ; Leak RK
    Pharmacol Res; 2019 Dec; 150():104371. PubMed ID: 31415915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine Models of Huntington's Disease for Evaluating Therapeutics.
    Kosior N; Leavitt BR
    Methods Mol Biol; 2018; 1780():179-207. PubMed ID: 29856020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.
    Wang LH; Qin ZH
    Acta Pharmacol Sin; 2006 Oct; 27(10):1287-302. PubMed ID: 17007735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transgenic mouse models of Parkinson's disease and Huntington's disease.
    Skaper SD; Giusti P
    CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):455-70. PubMed ID: 20522011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large Animal Models of Huntington's Disease: What We Have Learned and Where We Need to Go Next.
    Howland D; Ellederova Z; Aronin N; Fernau D; Gallagher J; Taylor A; Hennebold J; Weiss AR; Gray-Edwards H; McBride J
    J Huntingtons Dis; 2020; 9(3):201-216. PubMed ID: 32925082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease.
    Gil JM; Rego AC
    Brain Res Rev; 2009 Mar; 59(2):410-31. PubMed ID: 19118572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic neurodegenerative diseases: the human illness and transgenic models.
    Price DL; Sisodia SS; Borchelt DR
    Science; 1998 Nov; 282(5391):1079-83. PubMed ID: 9804539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.
    Chang R; Liu X; Li S; Li XJ
    Drug Des Devel Ther; 2015; 9():2179-88. PubMed ID: 25931812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Rodent Models of Huntington Disease.
    Stricker-Shaver J; Novati A; Yu-Taeger L; Nguyen HP
    Adv Exp Med Biol; 2018; 1049():29-57. PubMed ID: 29427097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental models of HD and reflection on therapeutic strategies.
    Kim J; Bordiuk OL; Ferrante RJ
    Int Rev Neurobiol; 2011; 98():419-81. PubMed ID: 21907096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Huntingtons Disease: The Value of Transcranial Meganetic Stimulation.
    Medina FJ; Túnez I
    Curr Med Chem; 2010; 17(23):2482-91. PubMed ID: 20491647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.
    Li JY; Popovic N; Brundin P
    NeuroRx; 2005 Jul; 2(3):447-64. PubMed ID: 16389308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.